The National Institutes of Health this week announced several new clinical trials studying different types of COVID-19 treatments.One new Phase 3 clinical trial (https://clinicaltrials.gov/ct2/show/NCT04843761?term=NCT04843761&draw=2&rank=1) will evaluate NeuroRx Inc.'s experimental formulation of aviptadil acetate and Gilead Sciences Inc.' (GILD) Veklury in hospitalized COVID-19 patients with acute respiratory distress syndrome. The trial will give participants a combination of the two drugs; aviptadil and a placebo; Veklury and a placebo; or only a placebo, and will initially enroll 40 patients. The NIH also said it added SAB Biotherapeutics Inc.'s investigational polyclonal antibody drug to an ongoing Phase 2/3 study (https://clinicaltrials.gov/ct2/show/NCT04518410?term=ACTIV-2&draw=2) evaluating possible COVID-19 treatments in people with mild or moderate cases of COVID-19. That therapy will be tested against a placebo. NeuroRx and SAB are privately held companies. And, finally, the NIH said it plans to initiate a Phase 3 clinical trial evaluating over-the-counter medications that people with COVID-19 can take at home. Roughly 13,500 participants in this new study will receive a placebo or one of seven treatments in the mail. The list of medications is still being finalized.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.